Kymab is discovering and developing fully human monoclonal antibody therapeutics using our pioneering Kymouse™ platform. We are building a rich pipeline of assets in four therapeutic spaces: immuno-oncology, inflammation, haematology and infectious diseases.

The Kymouse strains have more base-pairs of the human immunoglobulin genes than any other model. Their performance is exceptional: virtually every mouse responds to challenge, producing high-titre polyclonal antibodies to a variety of antigens including highly conserved human antigens.

Company Growth (employees)
Type
Private
HQ
Babraham, GB
Founded
2009
Size (employees)
127 (est)
Website
kymab.com
Kymab was founded in 2009 and is headquartered in Babraham, GB

Key People/Management at Kymab

David Chiswell

David Chiswell

Chief Executive Officer
Anne Hyland

Anne Hyland

Chief Financial Officer
Glenn Friedrich

Glenn Friedrich

Chief Operating Officer
Sonia Quaratino

Sonia Quaratino

Chief Medical Officer
Jasper Clube

Jasper Clube

Senior Vice President, Intellectual Property and Chief Patent Counsel
Nigel Clark

Nigel Clark

Senior Vice President, Business Development
Allan Bradley

Allan Bradley

Chief Technical Officer
Arndt Schottelius

Arndt Schottelius

Executive Vice President, R&D

Kymab Office Locations

Kymab has offices in Babraham and Taipei
Babraham, GB (HQ)
Meditrina Building, 260 Babraham Research Campus

Kymab Financials and Metrics

Summary Metrics

Founding Date

2009

Total Funding

$220.4 m

Latest funding size

$100 m

Time since last funding

12 months

Investors

Kymab's latest funding round in November 2016 was reported to be $100 m. In total, Kymab has raised $220.4 m

Kymab Financials

GBPFY, 2011FY, 2012

Current Assets

11

Total Assets

11

Additional Paid-in Capital

11

Total Equity

11
    Y, 2012

    Financial Leverage

    1 x
    Show all financial metrics

    Kymab's Web-traffic and Trends

    Kymab Company Life and Culture

    You may also be interested in